Comparative Pharmacology
Head-to-head clinical analysis: MICROGESTIN 1 5 30 versus WOLFINA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MICROGESTIN 1 5 30 versus WOLFINA.
MICROGESTIN 1.5/30 vs WOLFINA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive containing norethindrone acetate (progestin) and ethinyl estradiol (estrogen). Suppresses gonadotropin secretion (FSH, LH) via negative feedback on hypothalamic-pituitary axis, preventing ovulation. Also increases cervical mucus viscosity and alters endometrial receptivity.
Not specified in available data; likely unapproved or investigational drug.
One tablet (norethindrone acetate 1.5 mg/ethinyl estradiol 30 mcg) orally once daily at the same time each day for 21 consecutive days, followed by 7 days of placebo tablets.
Initial: 50 mg orally twice daily. Titrate to 100 mg twice daily after 2 weeks based on tolerability.
None Documented
None Documented
Norethindrone: 8-11 hours; Ethinyl estradiol: 13-19 hours. Steady-state reached within 5-7 days.
Terminal elimination half-life is 12-18 hours in healthy adults; prolonged to 24-36 hours in renal impairment (CrCl <30 mL/min), requiring dose adjustment.
Renal: ~50-60% (primarily as glucuronide conjugates of ethinyl estradiol and norethindrone); Fecal: ~40-50% (via biliary elimination)
Primarily renal (70% unchanged), with 20% biliary/fecal and 10% metabolic degradation.
Category C
Category C
Oral Contraceptive
Oral Contraceptive